ArticleSurgical innovation2013
Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.
Article in Surgical innovation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Intraoperative Doppler Verification of Arterial Occlusion in Minimally Invasive Renal Resection.Urologia internationalis · 2026Article
- Application of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).Oncology letters · 2026Review
- First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.European journal of nuclear medicine and molecular imaging · 2024Article
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Follow-up after curative treatment of localised renal cell carcinoma.World journal of urology · 2018Review
- Cancer Drug Development of Carbonic Anhydrase Inhibitors beyond the Active Site.Molecules (Basel, Switzerland) · 2018Review
- A Dual Reporter Iodinated Labeling Reagent for Cancer Positron Emission Tomography Imaging and Fluorescence-Guided Surgery.Journal of medicinal chemistry · 2018Article
- Post partial nephrectomy surveillance imaging: an evidence-based approach.Current urology reports · 2015Review
- Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule.International journal of oncology · 2015Article
- Article
- Mapping biological behaviors by application of longer-lived positron emitting radionuclides.Advanced drug delivery reviews · 2013Review
- Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions.Integrative biology : quantitative biosciences from nano to macro · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) accounts for approximately 85% to 90% of all primary kidney malignancies, with clear cell RCC (ccRCC) constituting approximately 70% to 85% of all RCCs. This study describes an innovative multimodal imaging and detection strategy that uses (124)I-labeled chimeric monoclonal antibody G250 ((124)I-cG250) for accurate preoperative and intraoperative localization and confirmation of extent of disease for both laparoscopic and open surgical resection of ccRCC. Two cases presented herein highlight how this technology can potentially guide complete surgical resection and confirm complete removal of all diseased tissues. This innovative (124)I-cG250 (ie, (124)I-girentuximab) multimodal imaging and detection approach, which would be clinically very useful to urologic surgeons, urologic medical oncologists, nuclear medicine physicians, radiologists, and pathologists who are involved in the care of ccRCC patients, holds great potential for improving the diagnostic accuracy, operative planning and approach, verification of disease resection, and monitoring for evidence of disease recurrence in ccRCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.